Inoculation target
This product is suitable for women aged 9-45.
This time, a nine-price reservation will be implemented to expand the age group. Look at the latest news, the updated version of HPV9 price specification has come out, 9-45 years old.
At present, it has not been confirmed that the product has the function of preventing diseases for people infected with the human papillomavirus contained in the vaccine. The risk of exposure to human papillomavirus increases with age, especially after sexual life begins, so it is recommended to vaccinate as soon as possible.
Immunization procedure and dosage
It is suggested that 1 dose should be inoculated in October, February and June, with 3 doses of 0.5mL each.
According to clinical research data, the inoculation interval between the second dose and the first dose is at least 1 month, while the inoculation interval between the third dose and the second dose is at least 3 months, and all three doses should be completed within one year.
Whether the product needs immunization has not been determined.
taboo
1. It is forbidden to cause hypersensitivity to the active ingredients or any auxiliary ingredients of the nine-valent or four-valent HPV vaccine.
2. Those who have hypersensitivity symptoms after injecting nine-valent or four-valent HPV vaccine should not be vaccinated again.
Medication for pregnant and lactating women
be pregnant
At present, no research has been conducted to evaluate the impact of this product on pregnant women. The limited data collected in pregnant women is not enough to judge whether vaccination with this product will lead to the risk of adverse pregnancy. Avoid vaccination during pregnancy. If a woman is pregnant or ready to get pregnant, it is recommended to postpone or interrupt the vaccination and wait until the pregnancy is over.
Lactating women
In clinical trials, antibody secretion induced by breast milk has not been observed. Because many drugs can be secreted by breast milk, lactating women should use them with caution.
drug interaction
1. Avoid using immunoglobulin or blood products within three months before inoculation.
2. At present, there is no clinical data to support that this product can be used interchangeably with other HPV vaccines. If you plan to vaccinate the nine-valent HPV vaccine after three doses of tetravalent HPV vaccine, you can start to vaccinate the product at least after 12 months, and the vaccination time is three doses.